Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Galmed Pharmaceuticals ( (GLMD) ) just unveiled an announcement.
On March 4, 2026, Galmed Pharmaceuticals convened a Special General Meeting of Shareholders in Ramat Gan, Israel, but the meeting was adjourned for one day because a quorum was not present. The session was rescheduled to reconvene on March 5, 2026, at the same time and location, a procedural delay that underscores ongoing corporate governance processes but does not itself signal a change in the company’s strategic direction.
The company also noted that this March 4, 2026 filing is incorporated by reference into its existing U.S. registration statements on Forms S-8 and F-3, maintaining the legal linkage between the shareholder meeting disclosure and its securities offerings. This step helps ensure continued regulatory compliance and transparency for investors in Galmed’s listed securities, while the adjournment highlights the practical importance of shareholder participation in key corporate decisions.
The most recent analyst rating on (GLMD) stock is a Hold with a $0.68 price target. To see the full list of analyst forecasts on Galmed Pharmaceuticals stock, see the GLMD Stock Forecast page.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Neutral.
The score is weighed down mainly by weak financial performance (no revenue, ongoing losses, and continued cash burn), with technicals also bearish as the stock trades below all major moving averages and momentum indicators remain negative. A debt-free balance sheet provides some stabilization but is not enough to offset the core operating risks.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies, with its shares listed in the United States as a foreign private issuer. The company is subject to U.S. securities regulation and regularly files reports with the Securities and Exchange Commission under Form 20-F and related registration statements.
Average Trading Volume: 90,136
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.35M
See more data about GLMD stock on TipRanks’ Stock Analysis page.